Results 11 to 20 of about 282,663 (297)

Introducing heat-not-burn tobacco improves hematocrit and cigarette smoking-related symptoms in patients with smokers' polycythemia and polycythemia vera. [PDF]

PLoS ONE
Cigarette smoking induces relative and absolute erythrocytosis (smokers' polycythemia). In patients with smokers' polycythemia complicated by chronic obstructive pulmonary disease, the incidence and mortality rate of pulmonary embolism increase ...
Kazuhide Iizuka, Yoshikazu Iizuka, Shun Ito, Toshihide Endo, Hironao Nukariya, Yuichi Takeuchi, Takashi Koike, Kazuya Kurihara, Hiromichi Takahashi, Masaru Nakagawa, Takashi Hamada, Shimon Ohtake, Noriyoshi Iriyama, Katsuhiro Miura, Tomohiro Nakayama, Yoshihiro Hatta, Hideki Nakamura, Norio Komatsu   +17 more
doaj   +2 more sources

Myelopathy due to Spinal Extramedullary Hematopoiesis in a Patient with Polycythemia Vera [PDF]

Case Reports in Orthopedics, 2017
Extramedullary hematopoiesis (EMH) occasionally occurs in patients exhibiting hematological disorders with decreased hematopoietic efficacy. EMH is rarely observed in the spinal epidural space and patients are usually asymptomatic.
Shuhei Ito, Nobuyuki Fujita, Naobumi Hosogane, Narihito Nagoshi, Mitsuru Yagi, Akio Iwanami, Kota Watanabe, Takashi Tsuji, Masaya Nakamura, Morio Matsumoto, Ken Ishii   +10 more
doaj   +3 more sources

Aquagenic Pruritus in Polycythemia Vera: Clinical Characteristics

Acta Dermato-Venereologica, 2018
Aquagenic pruritus is one of the main clinical features of polycythemia vera. The aim of this study was to analyse the clinical characteristics of aquagenic pruritus.
Edyta Lelonek, Łukasz Matusiak, Tomasz Wróbel, Jacek C. Szepietowski   +3 more
doaj   +2 more sources

Schizophrenia and Polycythemia Vera: A Case Report [PDF]

European Psychiatry
Introduction Schizophrenia is a severe mental disorder marked by abnormal interpretations of reality, often resulting in hallucinations, delusions, and disordered thinking that significantly impairs daily functioning and can be disabling.
N. El Moussaoui, S. Bahetta, I. Belabbes, F. Laboudi, A. Ouanass   +4 more
doaj   +2 more sources

Hematologic and molecular responses to ropeginterferon alfa-2b therapy of polycythemia vera: 48-week results from a prospective study. [PDF]

Int J Cancer
What's new? Current treatment goals for polycythemia vera, a myeloproliferative neoplasm characterized by JAK2 mutations, are mainly to prevent thrombosis. While ropeginterferon alfa‐2b treatment also reduces JAK2 mutation burden, the correlation between the hematologic and molecular responses remains to be clarified.
Yoon SY, Yoon SS, Yang DH, Lee GW, Sohn SK, Shin HJ, Bae SH, Choi CW, Choi EJ, Cheong JW, Bang SM, Park JS, Oh SJ, Park Y, Park YH, Lee SE.   +15 more
europepmc   +2 more sources

Polycythemia vera: 2024 update on diagnosis, risk‐stratification, and management

American journal of hematology/oncology, 2023
Polycythemia vera (PV) is a JAK2‐mutated myeloproliferative neoplasm characterized by clonal erythrocytosis; other features include leukocytosis, thrombocytosis, splenomegaly, pruritus, constitutional symptoms, microcirculatory disturbances, and ...
A. Tefferi, T. Barbui
semanticscholar   +1 more source

Population Pharmacokinetics-Pharmacodynamics and Exposure-Response of Ropeginterferon Alfa-2b in Chinese and Japanese Patients With Polycythemia Vera. [PDF]

Pharmacol Res Perspect
ABSTRACT Ropeginterferon alfa‐2b (ropeg) represents a new‐generation interferon‐based therapy approved for polycythaemia vera (PV) treatment. This study aimed to elucidate its population pharmacokinetics‐pharmacodynamics (PopPK‐PD) and exposure‐response (E‐R) relationships.
Qin A, Shimoda K, Suo S, Fu R, Kirito K, Wu D, Liao J, Chen H, Wu L, Su X, Gao Y, Sato T, Li Y, Zhang J, Shen W, Wang W, Zhang L, Jin J, Komatsu N.   +18 more
europepmc   +2 more sources

Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera.

NEJM Evidence, 2023
Ropeginterferon for Patients with Polycythemia VeraPatients with low-risk polycythemia vera were randomly assigned to receive ropeginterferon alfa-2b and phlebotomy or phlebotomy alone.
T. Barbui, A. Vannucchi, V. De Stefano, A. Carobbio, A. Ghirardi, Greta Carioli, A. Masciulli, E. Rossi, F. Ciceri, M. Bonifacio, A. Iurlo, F. Palandri, G. Benevolo, F. Pane, A. Ricco, G. Carli, M. Caramella, D. Rapezzi, C. Musolino, S. Siragusa, E. Rumi, A. Patriarca, N. Cascavilla, B. Mora, E. Cacciola, C. Mannarelli, G. G. Loscocco, P. Guglielmelli, F. Gesullo, S. Betti, F. Lunghi, L. Scaffidi, C. Bucelli, N. Vianelli, M. Bellini, M. Finazzi, G. Tognoni, A. Rambaldi   +37 more
semanticscholar   +1 more source

JAK2V617F allele burden in polycythemia vera: burden of proof

Blood, 2023
Visual ...
A. Moliterno, H. Kaizer, B. Reeves
semanticscholar   +1 more source

A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia

Blood, 2022
Therapy for essential thrombocythemia (ET) and polycythemia vera (PV) is aimed at reducing thrombotic risk through normalizing blood counts. Mascarenhas et al report on a randomized trial of hydroxyurea (HU) vs pegylated interferon α (PEG) in 168 ...
J. Mascarenhas, H. Kosiorek, J. Prchal, A. Rambaldi, Dmitriy Berenzon, A. Yacoub, C. Harrison, M. McMullin, A. Vannucchi, J. Ewing, C. O'Connell, J. Kiladjian, A. Mead, E. Winton, D. Leibowitz, V. De Stefano, M. Arcasoy, C. Kessler, R. Catchatourian, D. Rondelli, R. Silver, A. Bacigalupo, A. Nagler, M. Kremyanskaya, M. Levine, J. A. Arango Ossa, E. McGovern, L. Sandy, M. Salama, V. Najfeld, J. Tripodi, N. Farnoud, A. Penson, R. Weinberg, L. Price, J. Goldberg, R. Marchioli, G. Tognoni, R. Rampal, R. Mesa, A. Dueck, R. Hoffman, T. Barbui   +42 more
semanticscholar   +1 more source